<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Veldkamp, Kars I.</style></author><author><style face="normal" font="default" size="100%">Evers, Luc J.W.</style></author><author><style face="normal" font="default" size="100%">van Laarhoven, Twan</style></author><author><style face="normal" font="default" size="100%">Raykov, Yordan P.</style></author><author><style face="normal" font="default" size="100%">Little, Max A.</style></author><author><style face="normal" font="default" size="100%">Ho, King Chung</style></author><author><style face="normal" font="default" size="100%">Shin, Sooyoon</style></author><author><style face="normal" font="default" size="100%">Lehmann, Lisa Soleymani</style></author><author><style face="normal" font="default" size="100%">Bloem, Bastiaan R.</style></author><author><style face="normal" font="default" size="100%">Brouwer, Marc A.</style></author><author><style face="normal" font="default" size="100%">Thannhauser, Jos</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Heart rate monitoring using wrist photoplethysmography in Parkinson disease: feasibility and relation with autonomic dysfunction</style></title><secondary-title><style face="normal" font="default" size="100%">medRxiv</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-01-01 00:00:00</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">2025.08.15.25333751</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.1101/2025.08.15.25333751</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">Background Cardiac autonomic dysfunction is a prevalent yet underdiagnosed non-motor manifestation in Parkinson disease (PD), and difficult to monitor in daily life. Wrist-worn photoplethysmography (PPG) allows for continuous pulse rate monitoring, with potential to measure cardiac autonomic dysfunction in PD. However, motion artifacts pose significant challenges. We propose a two-step approach to account for PPG motion artifacts, and explore the association between pulse rate characteristics and cardiac autonomic dysfunction in PD.Methods In 444 people with early PD, we used continuous wrist PPG and accelerometer data, collected during two weeks, with an average wear time of 22h/day. Step 1 filters low-quality segments based on PPG morphology using a logistic regression classifier. Step 2 removes remaining segments with periodic motion artifacts (e.g. introduced by tremor). Weekly aggregates were calculated for resting (day, night) and maximum (day) pulse rates. We studied the effect of filtering on the pulse rate estimates and assessed the relationship between pulse rate aggregates and both subjective and objective autonomic dysfunction measures.Results Median proportion of high-quality PPG data was 29.2% [IQR: 24.0% to 35.9%] during the day, and 86.1% [IQR: 79.3% to 90.6%] during the night. Proportions of high-quality PPG data were similar across different rest tremor severity and dyskinesia scores. However, filtering out periodic motion artifacts (step 2) reduced overestimation of the maximum HR in persons with mild or severe rest tremor. More symptoms of autonomic dysfunction were associated with a lower maximum pulse rate during the day (β:-0.17, 95% CI: [−0.33, −0.00]), while resting pulse rate showed no association. No significant differences in pulse rate metrics were found between individuals with or without orthostatic hypotension.Conclusions PPG-based heart rate estimation in PD improves when periodic motion artifacts are accommodated, representing an important step toward developing digital biomarkers of cardiac autonomic dysfunction. Maximum pulse rate in daily life only demonstrated a weak association with autonomic dysfunction, highlighting the need for more specific markers such as pulse rate variability.Key contributions/strengths:- Careful signal quality assessment, taking into account periodic artifacts by combining PPG and accelerometer- Careful HR estimation using smoothed-pseudo Wigner-Ville, tested on an independent dataset.- Evaluation on a unique large PPG dataset from people with PD- Correlation to the clinical gold standard for autonomic dysfunction- Pipeline open source availableCompeting Interest StatementAuthors KCH, SS and LSL are currently employed by, and currently hold shares in, Verily Life Sciences, but declare no nonfinancial competing interests. Author BRB serves as the co-Editor in Chief for the Journal of Parkinsons disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for the Critical Path Institute, Gyenno Science, MedRhythms, UCB, Kyowa Kirin and Zambon (paid to the Institute), has received fees for speaking at conferences from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB and Zambon (paid to the Institute), and has received research support from Biogen, Cure Parkinsons, Davis Phinney Foundation, Edmond J. Safra Foundation, Fred Foundation, Gatsby Foundation, Hersenstichting Nederland, Horizon 2020, IRLAB Therapeutics, Maag Lever Darm Stichting, Michael J Fox Foundation, Ministry of Agriculture, Ministry of Economic Affairs &amp; Climate Policy, Ministry of Health, Welfare and Sport, Netherlands Organization for Scientific Research (ZonMw), Not Impossible, Parkinson Vereniging, Parkinsons Foundation, Parkinsons UK, Stichting Alkemade-Keuls, Stichting Parkinson NL, Stichting Woelse Waard, Health Holland / Topsector Life Sciences and Health, UCB, Verily Life Sciences, Roche and Zambon. Author BRB does not hold any stocks or stock options with any companies that are connected to Parkinsons disease or to any of his clinical or research activities. All other authors declare no competing interests.Funding StatementThis work was financially supported by the Michael J Fox Foundation (grant #020425), the Dutch Research Council (grant #ASDI.2020.060 &amp; grant #2023.010), the Dutch Research Council Long-Term Program (project #KICH3.LTP.20.006, financed by the Dutch Research Council, Verily, and the Dutch Ministry of Economic Affairs and Climate Policy), and by the Dutch Ministry of Economic Affairs (Topconsortium voor Kennis en Innovatie, Life Sciences &amp; Health, grant #LSHM20090-H048). The Radboudumc Center of Expertise for Parkinsons and Movement Disorders was supported by a center of excellence grant from the Parkinsons Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received approval from the Commissie Mensgebonden Onderzoek Region Arnhem-Nijmegen, and all participants provided informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes</style></abstract></record></records></xml>